MARKET

ARDS

ARDS

Aridis Pharmaceuticals Inc
EXMKT
0.0002
-0.0020
-90.91%
Closed 13:50 12/12 EST
OPEN
0.0002
PREV CLOSE
0.0022
HIGH
0.0002
LOW
0.0002
VOLUME
1.47K
TURNOVER
0
52 WEEK HIGH
2.770
52 WEEK LOW
0.0001
MARKET CAP
8.91K
P/E (TTM)
-0.0011
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at ARDS last week (1201-1205)?
Weekly Report · 4d ago
Weekly Report: what happened at ARDS last week (1124-1128)?
Weekly Report · 12/01 10:21
Weekly Report: what happened at ARDS last week (1117-1121)?
Weekly Report · 11/24 10:26
Weekly Report: what happened at ARDS last week (1110-1114)?
Weekly Report · 11/17 10:26
Weekly Report: what happened at ARDS last week (1103-1107)?
Weekly Report · 11/10 10:24
Weekly Report: what happened at ARDS last week (1027-1031)?
Weekly Report · 11/03 10:24
Weekly Report: what happened at ARDS last week (1020-1024)?
Weekly Report · 10/27 10:27
Weekly Report: what happened at ARDS last week (1013-1017)?
Weekly Report · 10/20 10:24
More
About ARDS
Aridis Pharmaceuticals, Inc. is a late-stage biopharmaceutical company. The Company is focused on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAbs) to treat life-threatening infections. The Company's product pipeline is comprised of fully human mAbs targeting specific pathogens associated with life-threatening bacterial and viral infections, primarily hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP), and cystic fibrosis. The Company's lead product candidates, AR-301 and AR-320, target the alpha toxin produced by the gram-positive bacteria Staphylococcus aureus (S. aureus), a common pathogen associated with HAP and VAP. The Company’s clinical development activities are primarily focused on AR-301, AR-320, and AR-501. Its MabIgX and lPEX discovery platforms enable the Company to rapidly screen, identify, and optimize fully human therapeutic mAb product candidates directly from the B-cells of patients.

Webull offers Aridis Pharmaceuticals Inc stock information, including EXMKT: ARDS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ARDS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ARDS stock methods without spending real money on the virtual paper trading platform.